Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.55 |
| ▸ | NPY2R | P49146 | 7/20 | 0.54 |
| ▸ | NPY4R | P50391 | 7/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.54 |
| ▸ | NPY1R | P25929 | 5/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.51 |
| ▸ | CALCR | P30988 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30327364 | 0.88 | OPRM1 (0.54) | OPRM1OPRD1OPRK1NPY2RNPY4R | |
| SCHEMBL31575703 | 0.86 | NTSR1 (0.60) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL29418159 | 0.85 | SLC6A2 (0.64) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL30974385 | 0.85 | CALCRL (0.59) | OPRM1OPRD1OPRK1NPY2RNPY4R | |
| SCHEMBL30974423 | 0.85 | NTSR1 (0.58) | OPRM1OPRD1OPRK1NPY2RNPY4R | |
| SCHEMBL30262120 | 0.84 | NTSR1 (0.59) | NPY2RNPY4RNPY5RNPY1RSLC6A2 | |
| SCHEMBL31415949 | 0.84 | SLC6A2 (0.63) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30176465 | 0.84 | TFPI (0.61) | OPRM1OPRD1OPRK1NPY2RNPY4R | |
| SCHEMBL30980373 | 0.84 | NTSR1 (0.62) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29714014 | 0.83 | NTSR1 (0.64) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070946-A1 | TYR PEPTIDE COMPOSITIONS AND METHODS FOR USE | UNIV MIAMI (US) | 2026-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070946-A1 | TYR PEPTIDE COMPOSITIONS AND METHODS FOR USE | XPNPEP1, PRAP1, YBX1 | OPRM1 3454/4885OPRD1 3775/4885OPRK1 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.